Talphera Achieves 50% Enrollment in NEPHRO-CRRT Registrational Study.

Talphera, a specialty pharmaceutical company, has announced 50% patient enrollment in the NEPHRO-CRRT clinical trial. The company made significant changes to the trial, including a 60% reduction in patient enrollment and focusing on medical ICUs with nephrologists as principal investigators. The trial aims to develop innovative therapies for medically supervised settings.